Citations (73)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Ivan Jakovljevic, Djordje Petrovic, Ljubinka Joksovic, Ivan Lazarevic, Milena Jelikic-Stankov & Predrag Djurdjevic. (2015) Complex formation equilibria between aluminum(III), gadolinium(III) and yttrium(III) ions and some fluoroquinolone ligands. Potentiometric and spectroscopic study. Journal of Coordination Chemistry 68:24, pages 4272-4295.
Read now
Read now
Matthew S McKinney & Anne W Beaven. (2014) Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma. Blood and Lymphatic Cancer: Targets and Therapy 4, pages 45-59.
Read now
Read now
Burcu Aslan, Bulent Ozpolat, Anil K. Sood & Gabriel Lopez-Berestein. (2013) Nanotechnology in cancer therapy. Journal of Drug Targeting 21:10, pages 904-913.
Read now
Read now
Nelson Leung & Thomas E. Witzig. (2013) The use of 90yttrium-ibritumomab tiuxetan in patients on dialysis: what do we know regarding its pharmacokinetics?. Leukemia & Lymphoma 54:12, pages 2586-2587.
Read now
Read now
Patrick B Johnston, Cara Bondly & Ivana NM Micallef. (2006) Ibritumomab tiuxetan for non-Hodgkin’s lymphoma. Expert Review of Anticancer Therapy 6:6, pages 861-869.
Read now
Read now
Vladimir Tolmachev, Jörgen Carlsson & Hans Lundqvist. (2004) A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy
Availability of suitable radionuclides. Acta Oncologica 43:3, pages 264-275.
Read now
Read now
Articles from other publishers (67)
Yoon Jung Jang, Sang Moo Lim, Inki Lee, Byung Hyun Byun, Ilhan Lim, Byung Il Kim, Chang Woon Choi, Seung‐Sook Lee, Cheolwon Suh, Dok Hyun Yoon, Inho Kim, Seung‐Hyun Nam, Mark Hong Lee, Jong Ho Won, Jee Hyun Kong, Seong Hyun Jeong, Suk Joong Oh, Keon Woo Park, Jae Joon Han, Moo‐Kon Song, Sung Hyun Yang, Im Il Na, Hyo‐Rak Lee, Dong‐Yeop Shin & Hye Jin Kang. (2023)
Radioimmunotherapy with
131
I‐rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma
. Asia-Pacific Journal of Clinical Oncology 19:6, pages 690-696.
Crossref
Crossref
Ilana Schlam, Ruth Moges, Stefania Morganti, Sara M. Tolaney & Paolo Tarantino. (2023) Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2. Critical Reviews in Oncology/Hematology 190, pages 104090.
Crossref
Crossref
Yanni Hao, Wei-Chun Hsu, Craig S Parzynski, Evgeny Degtyarev, Lisa V Hampson, Aisha Masood & Wen-Hsing Wu. (2023) Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma. Journal of Comparative Effectiveness Research 12:7.
Crossref
Crossref
Eric O. Aboagye, Tara D. Barwick & Uwe Haberkorn. (2023) Radiotheranostics in oncology: Making precision medicine possible. CA: A Cancer Journal for Clinicians 73:3, pages 255-274.
Crossref
Crossref
Matthew Mei, Joycelynne Palmer, Nicole Ni-Chun Tsai, Jennifer Simpson, James O'Hearn, Anthony Stein, Stephen Forman, Ricardo Spielberger, Ji-Lian Cai, Myo Htut, Ryotaro Nakamura, Monzr M. Al Malki, Alex Herrera, Jeffrey Wong & Auayporn Nademanee. (2023) Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma. Clinical Lymphoma Myeloma and Leukemia.
Crossref
Crossref
Sarfaraz K. Niazi & Zamara Mariam. (2023) Reinventing Therapeutic Proteins: Mining a Treasure of New Therapies. Biologics 3:2, pages 72-94.
Crossref
Crossref
Surya K. De. 2023. Medicines for Cancer. Medicines for Cancer
413
458
.
Aohan Hu & Justin J. Wilson. 2023. Radiopharmaceutical Therapy. Radiopharmaceutical Therapy
123
144
.
James M. Griffin, Fiona M. Healy, Lekh N. Dahal, Yngvar Floisand & John F. Woolley. (2022) Worked to the bone: antibody-based conditioning as the future of transplant biology. Journal of Hematology & Oncology 15:1.
Crossref
Crossref
Dayana Nasr, Prashanth Ashok Kumar, Maroun Bou Zerdan, Ghanshyam Ghelani, Dibyendu Dutta, Stephen Graziano & Seah H. Lim. (2022) Radioimmunoconjugates in the age of modern immuno-oncology. Life Sciences 310, pages 121126.
Crossref
Crossref
Zsolt Szakács, Amar Lal, Jorgen Kristensen, Nelli Farkas, Zsombor Ritter, Szabolcs Kiss, Hussain Alizadeh & Anett Balikó. (2022) 90Y-ibritumomab Tiuxetan in B-cell Non-Hodgkin Lymphomas: Real-world Data From the United Arab Emirates. Advances in Radiation Oncology 7:5, pages 100882.
Crossref
Crossref
Lisa Bodei, Ken Herrmann, Heiko Schöder, Andrew M. Scott & Jason S. Lewis. (2022) Radiotheranostics in oncology: current challenges and emerging opportunities. Nature Reviews Clinical Oncology 19:8, pages 534-550.
Crossref
Crossref
Aanchal Udaynath Pareri, Arunkumar Singh Koijam & Chandan Kumar. (2022) Breaking the Silence of Tumor Response: Future Prospects of Targeted Radionuclide
Therapy. Anti-Cancer Agents in Medicinal Chemistry 22:10, pages 1845-1858.
Crossref
Crossref
Victor M. Miranda. (2022) Medicinal inorganic chemistry: an updated review on the status of metallodrugs and prominent metallodrug candidates. Reviews in Inorganic Chemistry 42:1, pages 29-52.
Crossref
Crossref
Baji Baba Shaik, Naresh Kumar Katari & Anand Krishnan. 2022. Engineered Nanomaterials for Innovative Therapies and Biomedicine. Engineered Nanomaterials for Innovative Therapies and Biomedicine
205
232
.
Anzhelika O. Fedotova, Bayirta V. Egorova, Galina A. Posypanova, Nikolay A. Titchenko, Derenik S. Khachatryan, Anton V. Kolotaev, Vasiliy N. Osipov & Stepan N. Kalmykov. (2021) Labeling and receptor affinity of an ultra‐short somatostatin analogue Thz‐Phe‐D‐Trp‐Lys‐Thr‐DOTA. Journal of Peptide Science 27:12.
Crossref
Crossref
Natalia Herrero Álvarez, David Bauer, Javier Hernández‐Gil & Jason S. Lewis. (2021) Recent Advances in Radiometals for Combined Imaging and Therapy in Cancer. ChemMedChem 16:19, pages 2909-2941.
Crossref
Crossref
Zlatko Dembic. (2020) Antitumor Drugs and Their Targets. Molecules 25:23, pages 5776.
Crossref
Crossref
Samieh Asadian, Hamed Mirzaei, Bagher Aziz Kalantari, Mohamad Reza Davarpanah, Morteza Mohamadi, Anastasia Shpichka, Leila Nasehi, Hamidreza Aboulkheyr Es, Peter Timashev, Mustapha Najimi, Nematollah Gheibi, Moustapha Hassan & Massoud Vosough. (2020) β-radiating radionuclides in cancer treatment, novel insight into promising approach. Pharmacological Research 160, pages 105070.
Crossref
Crossref
Cathy S. Cutler. (2019) Economics of New Molecular Targeted Personalized Radiopharmaceuticals. Seminars in Nuclear Medicine 49:5, pages 450-457.
Crossref
Crossref
Anzhelika Yakusheva, Nikolay Titchenko, Bayirta Egorova, Ekaterina Matazova, Natalya Podkhalyuzina, Vasily Osipov, Derenik Khachatryan, Dmitry Avdeev, Galina Posypanova & Stepan Kalmykov. (2019) From octreotide to shorter analogues: Synthesis, radiolabeling, stability. Journal of Labelled Compounds and Radiopharmaceuticals 62:11, pages 718-728.
Crossref
Crossref
Robert F. Graziano & John J. Engelhardt. 2019. Fc Mediated Activity of Antibodies. Fc Mediated Activity of Antibodies
13
34
.
A. Baus, C. Keilani, C.-S. Bich, F. Entine, M. Brachet, P. Duhamel, J.-C. Amabile, J.V. Malfuson & E. Bey. (2018) Complex upper arm reconstruction using an antero-lateral thigh free flap after an extravasation of Yttrium-90-ibritumomab Tiuxetan: A case report and literature review. Annales de Chirurgie Plastique Esthétique 63:2, pages 175-181.
Crossref
Crossref
Isabel Corraliza-Gorjón, Beatriz Somovilla-Crespo, Silvia Santamaria, Jose A. Garcia-Sanz & Leonor Kremer. (2017) New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness. Frontiers in Immunology 8.
Crossref
Crossref
Clément Bailly, Caroline Bodet-Milin, Caroline Rousseau, Alain Faivre-Chauvet, Françoise Kraeber-Bodéré & Jacques Barbet. (2017) Pretargeting for imaging and therapy in oncological nuclear medicine. EJNMMI Radiopharmacy and Chemistry 2:1.
Crossref
Crossref
Licia Uccelli, Petra Martini, Micol Pasquali & Alessandra Boschi. (2017) Monoclonal Antibodies Radiolabeling with Rhenium-188 for Radioimmunotherapy. BioMed Research International 2017, pages 1-7.
Crossref
Crossref
Jie Xiao, Xiaobo Xu, Xiao Li, Yanli Li, Guobing Liu, Hui Tan, Hua Shen, Hongcheng Shi & Dengfeng Cheng. (2016) Re-188 Enhances the Inhibitory Effect of Bevacizumab in Non-Small-Cell Lung Cancer. Molecules 21:10, pages 1308.
Crossref
Crossref
Bayirta V. Egorova, Maxim S. Oshchepkov, Yury V. Fedorov, Olga A. Fedorova, Gleb S. Budylin, Evgeny A. Shirshin & Stepan N. Kalmykov. (2016)
Complexation of Bi
3+
, Ac
3+
, Y
3+
, Lu
3+
, La
3+
and Eu
3+
with benzo-diaza-crown ether with carboxylic pendant arms
. Radiochimica Acta 104:8, pages 555-565.
Crossref
Crossref
Saurabh Jain, Luca Aresu, Stefano Comazzi, Jianguo Shi, Erin Worrall, John Clayton, William Humphries, Sandra Hemmington, Paul Davis, Euan Murray, Asmare A. Limeneh, Kathryn Ball, Eva Ruckova, Petr Muller, Borek Vojtesek, Robin Fahraeus, David Argyle & Ted R. Hupp. (2016) The Development of a Recombinant scFv Monoclonal Antibody Targeting Canine CD20 for Use in Comparative Medicine. PLOS ONE 11:2, pages e0148366.
Crossref
Crossref
Đorđe Petrović, Ivan Jakovljević, Ljubinka Joksović, Katalin Meszaros Szecsenyi & Predrag Đurđević. (2016) Study of the hydrolytic properties of the trivalent Y-ion in chloride medium. Polyhedron 105, pages 1-11.
Crossref
Crossref
Vidya Ganapathy, Prabhas V. Moghe & Charles M. Roth. (2015) Targeting tumor metastases: Drug delivery mechanisms and technologies. Journal of Controlled Release 219, pages 215-223.
Crossref
Crossref
Andrew B. Satterlee, Hong Yuan & Leaf Huang. (2015) A radio-theranostic nanoparticle with high specific drug loading for cancer therapy and imaging. Journal of Controlled Release 217, pages 170-182.
Crossref
Crossref
Manjari Pandey & Daruka Mahadevan. (2014) Monoclonal antibodies as therapeutics in human malignancies. Future Oncology 10:4, pages 609-636.
Crossref
Crossref
Flavio Forrer, Catharina Oechslin-Oberholzer, Benedetta Campana, Richard Herrmann, Helmut R. Maecke, Jan Mueller-Brand & Andreas Lohri. (2013)
Radioimmunotherapy with
177
Lu-DOTA-Rituximab: Final Results of a Phase I/II Study in 31 Patients with Relapsing Follicular, Mantle Cell, and Other Indolent B-Cell Lymphomas
. Journal of Nuclear Medicine 54:7, pages 1045-1052.
Crossref
Crossref
Tapas Das & M.R.A. Pillai. (2013) Options to meet the future global demand of radionuclides for radionuclide therapy. Nuclear Medicine and Biology 40:1, pages 23-32.
Crossref
Crossref
Alan S. Wayne. 2013. Childhood Leukemias. Childhood Leukemias
563
581
.
C. Arrichiello, L. Aloj, M. Mormile, L. D’Ambrosio, F. Frigeri, C. Caracò, M. Arcamone, F. De Martinis, A. Pinto & S. Lastoria. (2012) Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with 90Y-ibritumomab tiuxetan. European Journal of Nuclear Medicine and Molecular Imaging 39:6, pages 956-966.
Crossref
Crossref
Roberta E Burden, Jill Caswell, Francois Fay & Christopher J Scott. (2012) Recent advances in the application of antibodies as therapeutics. Future Medicinal Chemistry 4:1, pages 73-86.
Crossref
Crossref
Veronica Goffredo, Angelo Paradiso, Girolamo Ranieri & Cosmo Damiano Gadaleta. (2011) Yttrium-90 (90Y) in the principal radionuclide therapies: An efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999–2009). Critical Reviews in Oncology/Hematology 80:3, pages 393-410.
Crossref
Crossref
Tim Illidge & Franck Morschhauser. (2011) Radioimmunotherapy in follicular lymphoma. Best Practice & Research Clinical Haematology 24:2, pages 279-293.
Crossref
Crossref
Toni Valković, Antica Duletić-Načinović, Sanja Štifter, Milena Hasan, Ita Hadžisejdić, David Zombori, Blaženka Grahovac & Nives Jonjić. (2010) Macrophage chemotactic protein-1 mRNA levels in non-Hodgkin lymphoma. Clinical and Experimental Medicine 10:4, pages 229-235.
Crossref
Crossref
Abmel Xiques Castillo, Marylaine Pérez-Malo, Keila Isaac-Olivé, Heyam Mukhallalati, Edgar Casanova González, Mirta Torres Berdeguez & Néstor Cornejo Díaz. (2010) Production of large quantities of 90Y by ion-exchange chromatography using an organic resin and a chelating agent. Nuclear Medicine and Biology 37:8, pages 935-942.
Crossref
Crossref
E. Lopci, I. Santi, E. Derenzini, C. Fonti, G. Savelli, F. Bertagna, M. Bellò, B. Botto, D. Huglo, F. Morschhauser, P. Zinzani & S. Fanti. (2010) FDG–PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study. Annals of Oncology 21:9, pages 1877-1883.
Crossref
Crossref
Andrei Ivanov, Ruth Swann & Tim Illidge. (2008) New insights into the mechanisms of action of radioimmunotherapy in lymphoma. Journal of Pharmacy and Pharmacology 60:8, pages 987-998.
Crossref
Crossref
Stephanie A. Gregory, Karin Hohloch, Christian Gisselbrecht, Kensei Tobinai & Martin Dreyling. (2009) Harnessing the Energy: Development of Radioimmunotherapy for Patients with Non-Hodgkin’s Lymphoma. The Oncologist 14:S2, pages 4-16.
Crossref
Crossref
Raphael Alford, Mikako Ogawa, Peter L. Choyke & Hisataka Kobayashi. (2009) Molecular probes for the in vivo imaging of cancer. Molecular BioSystems 5:11, pages 1279.
Crossref
Crossref
Antonio J. Grillo-López. 2009. Principles of Cancer Biotherapy. Principles of Cancer Biotherapy
613
629
.
A. A. McCormickS. ReddyS. J. ReinlT. I. CameronD. K. CzerwinkskiF. VojdaniK. M. HanleyS. J. GargerE. L. WhiteJ. NovakJ. Barrett, R. B. Holtz, D. TuséR. Levy. (2008) Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study. Proceedings of the National Academy of Sciences 105:29, pages 10131-10136.
Crossref
Crossref
Rubel Chakravarty, Usha Pandey, Remani B. Manolkar, Ashutosh Dash, Meera Venkatesh & M.R. Ambikalmajan Pillai. (2008) Development of an electrochemical 90Sr–90Y generator for separation of 90Y suitable for targeted therapy. Nuclear Medicine and Biology 35:2, pages 245-253.
Crossref
Crossref
Marc A. Becker & Douglas Yee. 2008. EGFR Signaling Networks in Cancer Therapy. EGFR Signaling Networks in Cancer Therapy
147
160
.
Drishty Satpati, Aruna Korde, Usha Pandey, Prem Dhami, Sharmila Banerjee & Meera Venkatesh. (2006) Synthesis and evaluation of90Y-DOTA-Colchicine conjugate in murine fibrosarcoma model. Journal of Labelled Compounds and Radiopharmaceuticals 49:11, pages 951-958.
Crossref
Crossref
Oliver Weigert, Tim Illidge, Wolfgang Hiddemann & Martin Dreyling. (2006) Recommendations for the use of Yttrium-90 ibritumomab tiuxetan in malignant lymphoma. Cancer 107:4, pages 686-695.
Crossref
Crossref
Dangshe Ma, Christine E. Hopf, Andrew D. Malewicz, Gerald P. Donovan, Peter D. Senter, William F. Goeckeler, Paul J. Maddon & William C. Olson. (2006) Potent Antitumor Activity of an Auristatin-Conjugated, Fully Human Monoclonal Antibody to Prostate-Specific Membrane Antigen. Clinical Cancer Research 12:8, pages 2591-2596.
Crossref
Crossref
KATHERINE MORLAND HAMMITT & ELAINE L. ALEXANDER. 2006. The Autoimmune Diseases. The Autoimmune Diseases
971
985
.
Jeongsoo Yoo, Lucie Tang, Todd A. Perkins, Douglas J. Rowland, Richard Laforest, Jason S. Lewis & Michael J. Welch. (2005) Preparation of high specific activity 86Y using a small biomedical cyclotron. Nuclear Medicine and Biology 32:8, pages 891-897.
Crossref
Crossref
Ingrid Burvenich, Steve Schoonooghe, Bart Cornelissen, Peter Blanckaert, Elisabeth Coene, Claude Cuvelier, Nico Mertens & Guido Slegers. (2005)
In vitro
and
In vivo
Targeting Properties of Iodine-123- or Iodine-131–Labeled Monoclonal Antibody 14C5 in a Non–Small Cell Lung Cancer and Colon Carcinoma Model
. Clinical Cancer Research 11:20, pages 7288-7296.
Crossref
Crossref
Gunhild Keller, Andrew V. Schally, Timo Gaiser, Attila Nagy, Benjamin Baker, Gabor Halmos & Jörg B. Engel. (2005) Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin’s lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207. European Journal of Cancer 41:14, pages 2196-2202.
Crossref
Crossref
A. Hagenbeek & V. Lewington. (2005) Report of a European consensus workshop to develop recommendations for the optimal use of 90Y-ibritumomab tiuxetan (Zevalin®) in lymphoma. Annals of Oncology 16:5, pages 786-792.
Crossref
Crossref
Gunhild Keller, Jörg B. Engel, Andrew V. Schally, Attila Nagy, Brian Hammann & Gabor Halmos. (2005) Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238. International Journal of Cancer 114:5, pages 831-835.
Crossref
Crossref
Seyed K. Imam. (2005) Molecular Nuclear Imaging: The Radiopharmaceuticals (Review). Cancer Biotherapy and Radiopharmaceuticals 20:2, pages 163-172.
Crossref
Crossref
Antonio J. Grillo-López. (2005) 90Y-ibritumomab tiuxetan: Rationale for patient selection in the treatment of indolent non-Hodgkin’s lymphoma. Seminars in Oncology 32, pages 44-49.
Crossref
Crossref
Myron S. Czuczman, Robin Weaver, Baha Alkuzweny, Judy Berlfein & Antonio J. Grillo-López. (2004) Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up. Journal of Clinical Oncology 22:23, pages 4711-4716.
Crossref
Crossref
Che-Leung Law, Charles G. Cerveny, Kristine A. Gordon, Kerry Klussman, Bruce J. Mixan, Dana F. Chace, Damon L. Meyer, Svetlana O. Doronina, Clay B. Siegall, Joseph A. Francisco, Peter D. Senter & Alan F. Wahl. (2004) Efficient Elimination of B-Lineage Lymphomas by Anti-CD20–Auristatin Conjugates. Clinical Cancer Research 10:23, pages 7842-7851.
Crossref
Crossref
Dan Lu, Haifan Zhang, Dale Ludwig, Anita Persaud, Xenia Jimenez, Douglas Burtrum, Paul Balderes, Meilin Liu, Peter Bohlen, Larry Witte & Zhenping Zhu. (2004) Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific Antibody. Journal of Biological Chemistry 279:4, pages 2856-2865.
Crossref
Crossref
Charles P. Theuer, Bryan R. Leigh, Pratik S. Multani, Roberta S. Allen & Bertrand C. Liang. 2004.
265
295
.
Ralf Ostendorp, Christian Frisch & Margit Urban. 2004. Antibodies. Antibodies
13
52
.
C. Norman Coleman. (2003) Linking Radiation Oncology and Imaging through Molecular Biology (or Now That Therapy and Diagnosis Have Separated, It’s Time to Get Together Again!). Radiology 228:1, pages 29-35.
Crossref
Crossref